BPC-157 Arginate — preclinical research summary

BPC-157 Arginate — oral stability data.

Preclinical stability and absorption data. Every number links to its source.

Open the research library →

The research landscape

Mapped from published science.

6
Support pathways mapped
8
Active compounds
3
Formula layers
20+
Studies referenced
9,543
subjects · SNAC (preclinical) delivery
1,996
subjects · PEA (preclinical)
-70%
gut permeability · Zinc-L-Carnosine

Architecture

Research compound architecture.
Multi-pathway preclinical data.

Tissue repair, gut barrier integrity, collagen synthesis, and anti-inflammatory signaling — all preclinical data. — combined into a single research compound formulation.

Explore preclinical research →

BPC-157 Arginate

The stabilized form.

*Backed by an ongoing peer-reviewed preclinical research.

BPC-157 research →

TB4-derived fragment

Not the TB-500 everyone sells.

30% oral bioavailability — where TB-500 delivers under 1%.

Fragment research →

PEA

Anti-inflammatory profile (preclinical).

PEA is included as the anti-inflammatory (preclinical)-siUp to 35% less anti-inflammatory (preclinical), month one — studied across 1,196 research subjects.

PEA research →

Gut barrier logic

The gut is a barrier,
not just a tube.

Zinc-L-Carnosine cut gut permeability by 70% in 14 days.

Gut barrier research →

Oral delivery logic

Built to survive the stomach.

×9 absorption with SNAC — the only oral peptide delivery technology approved by the FDA.

Delivery research →

Real science. Real authors.

The compounds in our formulas are studied by researchers at established institutions. We cite them — names, institutions, and work.

Researchers

RESEARCHERS

Experts in peptide science and peptide and biochemistry research

Research Data

RESEARCH DATA

Advanced Analytical Testing and Compound Verification

Published Research

PUBLISHED RESEARCH

Peer-reviewed studies in reputable research journals

Established Institutions

ESTABLISHED INSTITUTIONS

Collaborations with leading research institutions worldwide

Up to 20 cited authors / institutions populated during research phase. → See all sources

Research context

Published studies on compound classes.

Publicly available peer-reviewed research on these compound classes.. All data is preclinical. No human clinical trials conducted by Panstellar LLC.

Duration: [ x months ]Status: [ enrolling / completed ]
Duration: [ x months ]Status: [ status ]
Duration: [ x months ]Status: [ status ]

Compound comparison — research architecture

Research architecture comparison.

SignalInjection"BPC+TB-500" capsPanstellar
No needles✗✓✓
Oral TB that survivesn/a✗✓ SNAC carrier
FDA-approved carrier technology (SNAC)✗✗✓ Ac-SDKP
Gut-targeted~~✓
Tested every batch~✗✓

Comparison of compound delivery architecture only. No efficacy claims implied.

In the literature

Where these compounds appear in peer-reviewed discussion.

Podcasts, long-form video, and researchers discussing the research behind these compound classes.

Verification

Scan it. Open the report.

Every batch is third-party tested. Open the report yourself.

Verify a Batch →

Raw sources

Want the raw research?

Filter by product, ingredient, outcome, study type, and evidence level.

Open Research Library →